InsidersTradesSigma
Browse the full insider trade history of Akers Biosciences Inc, a listed equity based in United States. Shares are quoted on US US, under the supervision of SEC (Form 4). Market capitalisation: €5.4bn. The latest transaction was filed on 6 January 2016 (Acquisition). Among the most active insiders: Knox Thomas J. Every trade is accessible without an account.
Analysts rate Akers Biosciences Inc Hold (neutral), based on 2 analysts. Average price target: US$463.00.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
3 of 3 declarations
Akers Biosciences Inc is a company focused on developing medical diagnostic technologies. It specializes in innovative solutions for rapid and accurate testing.